Healthcare
Amgen Inc. (AMGN)
Data as of July 6, 2026
Environment story
Source documents contain no disclosed Scope 1/2/3 emissions data, renewable-electricity percentage, or a stated net-zero target year, resulting in default penalties for non-disclosure. No verifiable toxic-waste or water-consumption controversies are documented in the provided filings, and no verified physical decarbonization capital investment is quantified. This is descriptive research information, not investment advice.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
New Thousand Oaks R&D FacilityBroke ground in 2025 on a new R&D facility in Thousand Oaks, CA intended to enhance collaboration across R&D and process development.
Social story
Amgen reports approximately 31,500 staff across 50+ countries with low turnover and 'good' staff relations, including represented employees under unions/works councils outside the U.S. with no documented strikes or suppression activity in the source filings. Named executive officer leadership shown in the 10-K (10 officers) includes 2 women, placing technical/executive leadership representation under the 30% threshold, which is penalized per rubric. CEO-to-median-worker pay ratio and supply-chain human-rights audit results were not disclosed in the provided excerpts. This is descriptive research information, not investment advice.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Apprenticeship ProgramLaunched 2023 in Manufacturing/ATMOS functions, expanded to North Carolina site in 2025; skills-based hiring/upskilling for non-four-year-degree talent.Workforce development and broadened hiring pipeline
-
Total Workforce Health & Safety ProgramJob-specific safety training, incident tracking systems, quarterly executive safety reviews across Operations, Commercial and R&D.Safety performance monitoring
-
Flexible Workspace InitiativeEnables employees to determine work location in coordination with managers.Employee engagement
Governance story
Amgen maintains a single class of common shares with equal voting rights (no dual-class structure), no poison pill, no supermajority provisions, and 11 of 12 director nominees are independent (91.7%), exceeding the 75% threshold. A modest deduction is applied for an ongoing, unresolved IRS tax dispute (RAR issued for 2010-2012 tax years) disclosed as a material risk factor. No antitrust, consumer-safety, or financial-fraud consent decrees are documented in the provided filings, and no evidence of lobbying explicitly targeting climate or consumer-protection rollback was found in the source text. This is descriptive research information, not investment advice.
Criticisms on file
-
Ongoing IRS tax dispute regarding 2010-2012 tax years with proposed significant adjustmentsSource: AMGN_10k.txt
Disclosed initiatives
-
Clawback / Recoupment PoliciesMandatory no-fault clawback policy for erroneously awarded incentive compensation plus discretionary recoupment for misconduct.Executive accountability
-
Stockholder Rights ProvisionsProxy access, action by written consent (15% threshold), right to call special meetings (15% threshold), no supermajority vote provisions, no poison pill.Enhanced shareholder rights
These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Amgen Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Amgen Inc. in the app for interactive charts and portfolio building.
Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics